{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:04:54Z","timestamp":1790298294336,"version":"4.1.0"},"reference-count":45,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0616","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:24:09Z","timestamp":1525238649000},"source":"Crossref","is-referenced-by-count":57,"title":["The Diagnosis and Treatment of Optic Neuritis"],"prefix":"10.3238","author":[{"given":"Helmut","family":"Wilhelm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"key":"10.3238\/arztebl.2015.0616_ref1","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Anderson MM, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581\u20138","DOI":"10.1056\/NEJM199202273260901"},{"key":"10.3238\/arztebl.2015.0616_ref2","doi-asserted-by":"crossref","unstructured":"Langer-Gould A, Brara SM, Beaber BE, Zhang JL: The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol 2014; 261: 1349\u201355","DOI":"10.1007\/s00415-014-7349-0"},{"key":"10.3238\/arztebl.2015.0616_ref3","doi-asserted-by":"crossref","unstructured":"Morrow MJ, Wingerchuk D: Neuromyelitis optica. J Neuroophthalmol 2012; 32: 154\u201366","DOI":"10.1097\/WNO.0b013e31825662f1"},{"key":"10.3238\/arztebl.2015.0616_ref4","doi-asserted-by":"crossref","unstructured":"Davis FA, Bergen D, Schauf C, McDonald I, Deutsch W: Movement phosphenes in optic neuritis: a new clinical sign. Neurology 1976; 26: 1100\u20134","DOI":"10.1212\/WNL.26.11.1100"},{"key":"10.3238\/arztebl.2015.0616_ref5","doi-asserted-by":"crossref","unstructured":"Fraser CL, Davagnanam I, Radon M, Plant GT: The time course and phenotype of Uhthoff phenomenon following optic neuritis. Mult Scler 2011; 18: 1042\u20134","DOI":"10.1177\/1352458511431074"},{"key":"10.3238\/arztebl.2015.0616_ref6","doi-asserted-by":"crossref","unstructured":"Park K, Tanaka K, Tanaka M: Uhthoff\u2019s phenomenon in multiple sclerosis and neuromyelitis optica. Eur Neurol 2014; 72: 153\u20136","DOI":"10.1159\/000361045"},{"key":"10.3238\/arztebl.2015.0616_ref7","doi-asserted-by":"crossref","unstructured":"Keltner JL, Johnson CA, Spurr JO, Beck RW: Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993; 111: 231\u20134","DOI":"10.1001\/archopht.1993.01090020085029"},{"key":"10.3238\/arztebl.2015.0616_ref8","doi-asserted-by":"crossref","unstructured":"Horwitz H, Friis T, Modvig S, et al.: Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol 2014; 261: 98\u2013105","DOI":"10.1007\/s00415-013-7166-x"},{"key":"10.3238\/arztebl.2015.0616_ref9","doi-asserted-by":"crossref","unstructured":"Leo-Kottler B, Wissinger B: Lebersche Optikusneuropathie. Ophthalmologe 2011; 108: 1179\u201392; quiz 93\u20134","DOI":"10.1007\/s00347-011-2482-y"},{"key":"10.3238\/arztebl.2015.0616_ref10","doi-asserted-by":"crossref","unstructured":"Purvin V, Sundaram S, Kawasaki A: Neuroretinitis: review of the literature and new observations. J Neuroophthalmol 2011; 31: 58\u201368","DOI":"10.1097\/WNO.0b013e31820cf78a"},{"key":"10.3238\/arztebl.2015.0616_ref11","doi-asserted-by":"crossref","unstructured":"Trebst C, Jarius S, Berthele A, et al.: Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1\u201316","DOI":"10.1007\/s00415-013-7169-7"},{"key":"10.3238\/arztebl.2015.0616_ref12","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al.: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177\u201389","DOI":"10.1212\/WNL.0000000000001729"},{"key":"10.3238\/arztebl.2015.0616_ref13","doi-asserted-by":"crossref","unstructured":"Petzold A, Plant GT: Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2013; 261: 17\u201326","DOI":"10.1007\/s00415-013-6957-4"},{"key":"10.3238\/arztebl.2015.0616_ref14","unstructured":"Leitlinie Nr. 30 Neuritis nervi optici http:\/\/augeninfo.de\/leit\/leit30.pdf (last accessed on 27 July 2015)."},{"key":"10.3238\/arztebl.2015.0616_ref15","unstructured":"DGN \/ KKNMS Leitlinie zur Diagnose und Therapie der Multiplen Sklerose (last accessed on 23 July 2015)."},{"key":"10.3238\/arztebl.2015.0616_ref16","doi-asserted-by":"crossref","unstructured":"Optic Neuritis Study Group: Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727\u201332","DOI":"10.1001\/archneur.65.6.727"},{"key":"10.3238\/arztebl.2015.0616_ref17","doi-asserted-by":"crossref","unstructured":"Polman CH, Reingold SC, Banwell B, et al.: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292\u2013302","DOI":"10.1002\/ana.22366"},{"key":"10.3238\/arztebl.2015.0616_ref18","doi-asserted-by":"crossref","unstructured":"Marques IB, Matias F, Silva ED, Cunha L, Sousa L: Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 2013; 21: 583\u20136","DOI":"10.1016\/j.jocn.2013.06.013"},{"key":"10.3238\/arztebl.2015.0616_ref19","doi-asserted-by":"crossref","unstructured":"Oberwahrenbrock T, Schippling S, Ringelstein M, et al.: Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012; 2012: 530305","DOI":"10.1155\/2012\/530305"},{"key":"10.3238\/arztebl.2015.0616_ref20","doi-asserted-by":"crossref","unstructured":"Bennett JL, de Seze J, Lana-Peixoto M, et al.: Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler 2015; 21: 678\u201388","DOI":"10.1177\/1352458514567216"},{"key":"10.3238\/arztebl.2015.0616_ref21","doi-asserted-by":"crossref","unstructured":"Gal RL, Vedula SS, Beck R: Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2012; 4: CD001430","DOI":"10.1002\/14651858.CD001430.pub3"},{"key":"10.3238\/arztebl.2015.0616_ref22","doi-asserted-by":"crossref","unstructured":"Beck RW: The optic neuritis treatment trial. Implications for clinical practice. Optic Neuritis Study Group. Arch Ophthalmol 1992; 110: 331\u20132","DOI":"10.1001\/archopht.1992.01080150029020"},{"key":"10.3238\/arztebl.2015.0616_ref23","doi-asserted-by":"crossref","unstructured":"Diem R, Hobom M, Maier K, et al.: Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003; 23: 6993\u20137000","DOI":"10.1523\/JNEUROSCI.23-18-06993.2003"},{"key":"10.3238\/arztebl.2015.0616_ref24","doi-asserted-by":"crossref","unstructured":"Dimitriu C, Bach M, Lagreze WA, Jehle T: Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. Invest Ophthalmol Vis Sci 2008; 49: 5003\u20137","DOI":"10.1167\/iovs.08-1869"},{"key":"10.3238\/arztebl.2015.0616_ref25","doi-asserted-by":"crossref","unstructured":"Trobe JD, Sieving PC, Guire KE, Fendrick AM: The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology 1999; 106: 2047\u201353","DOI":"10.1016\/S0161-6420(99)90482-7"},{"key":"10.3238\/arztebl.2015.0616_ref26","doi-asserted-by":"crossref","unstructured":"Zivadinov R, Rudick RA, De Masi R, et al.: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239\u201347","DOI":"10.1212\/WNL.57.7.1239"},{"key":"10.3238\/arztebl.2015.0616_ref27","unstructured":"Le Page E, Veillard D, Laplaud DA, et al.: Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015 pii: S0140\u20136736 (15)61137\u20130."},{"key":"10.3238\/arztebl.2015.0616_ref28","doi-asserted-by":"crossref","unstructured":"Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J: A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479\u201384","DOI":"10.1212\/WNL.52.7.1479"},{"key":"10.3238\/arztebl.2015.0616_ref29","doi-asserted-by":"crossref","unstructured":"Schilling S, Linker RA, Konig FB, et al.: Plasmaaustausch bei steroidresistenten Multiple-Sklerose-Schuben: Klinische Erfahrungen an 16 Patienten. Nervenarzt 2006; 77: 430\u20138 CrossRef","DOI":"10.1007\/s00115-005-2019-1"},{"key":"10.3238\/arztebl.2015.0616_ref30","doi-asserted-by":"crossref","unstructured":"Merle H, Olindo S, Jeannin S, et al.: Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012; 130: 858\u201362 CrossRef","DOI":"10.1001\/archophthalmol.2012.1126"},{"key":"10.3238\/arztebl.2015.0616_ref31","doi-asserted-by":"crossref","unstructured":"Bennett JL, Nickerson M, Costello F, et al.: Re-evaluating the treatment of acute optic neuritis. J Neurol Neurosurg Psychiatry 2015; 86: 799\u2013808 MEDLINE","DOI":"10.1136\/jnnp-2014-308185"},{"key":"10.3238\/arztebl.2015.0616_ref32","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PW, Li D, Freedman MS, et al.: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894\u2013900","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"10.3238\/arztebl.2015.0616_ref33","doi-asserted-by":"crossref","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, et al.: Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293\u2013303","DOI":"10.1056\/NEJMoa1014656"},{"key":"10.3238\/arztebl.2015.0616_ref34","doi-asserted-by":"crossref","unstructured":"Gold R, Kappos L, Arnold DL, et al.: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098\u2013107 CrossRef","DOI":"10.1056\/NEJMoa1114287"},{"key":"10.3238\/arztebl.2015.0616_ref35","doi-asserted-by":"crossref","unstructured":"Ellrichmann G, Gold R: Multiple Sklerose \u2013 Therapie so fr\u00fch wie m\u00f6glich. Pro. Akt Neurol 2015; 42.","DOI":"10.1055\/s-0034-1387578"},{"key":"10.3238\/arztebl.2015.0616_ref36","doi-asserted-by":"crossref","unstructured":"Steinbrecher A: Multiple Sklerose \u2013 Therapie so fr\u00fch wie m\u00f6glich \u2013 Kontra. Akt Neurol 2015; 42: 97\u2013101","DOI":"10.1055\/s-0034-1387577"},{"key":"10.3238\/arztebl.2015.0616_ref37","doi-asserted-by":"crossref","unstructured":"Rudick RA, Mi S, Sandrock AW, Jr.: LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 2008; 8: 1561\u201370","DOI":"10.1517\/14712598.8.10.1561"},{"key":"10.3238\/arztebl.2015.0616_ref38","doi-asserted-by":"crossref","unstructured":"S\u00fchs K-W, Hein K, S\u00e4ttler MB, et al.: A randomized, double-blind, phase II study on erythropoietin in optic neuritis. Ann Neurol 2012: 199\u2013210","DOI":"10.1002\/ana.23573"},{"key":"10.3238\/arztebl.2015.0616_ref39","doi-asserted-by":"crossref","unstructured":"Tsakiri A, Kallenbach K, Fuglo D, Wanscher B, Larsson H, Frederiksen J: Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012; 18: 72\u201381","DOI":"10.1177\/1352458511415452"},{"key":"10.3238\/arztebl.2015.0616_ref40","doi-asserted-by":"crossref","unstructured":"Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898\u2013904","DOI":"10.1056\/NEJM200009283431301"},{"key":"10.3238\/arztebl.2015.0616_ref41","doi-asserted-by":"crossref","unstructured":"Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O\u2019Connor PW, Simon JH: Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the controlled high-risk avonex multiple sclerosis prevention study in ongoing neurological surveillance. Arch Neurol 2012; 69: 183\u201390","DOI":"10.1001\/archneurol.2011.1426"},{"key":"10.3238\/arztebl.2015.0616_ref42","doi-asserted-by":"crossref","unstructured":"Comi G, Filippi M, Barkhof F, et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576\u201382","DOI":"10.1016\/S0140-6736(00)04725-5"},{"key":"10.3238\/arztebl.2015.0616_ref43","doi-asserted-by":"crossref","unstructured":"Kappos L, Freedman MS, Polman CH, et al.: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389\u201397","DOI":"10.1016\/S0140-6736(07)61194-5"},{"key":"10.3238\/arztebl.2015.0616_ref44","doi-asserted-by":"crossref","unstructured":"Edan G, Kappos L, Montalban X, et al.: Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2014; 85: 1183\u20139 MEDLINE","DOI":"10.1136\/jnnp-2013-306222"},{"key":"10.3238\/arztebl.2015.0616_ref45","doi-asserted-by":"crossref","unstructured":"Comi G, Martinelli V, Rodegher M, et al.: Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503\u201311","DOI":"10.1016\/S0140-6736(09)61259-9"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:00:21Z","timestamp":1638781221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":45,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0616","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]}}}